Asensus Surgical, Inc. (NYSEAMERICAN:ASXC – Get Free Report) saw a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 12,890,000 shares, a growth of 13.9% from the June 30th total of 11,320,000 shares. Currently, 4.8% of the company’s shares are sold short. Based on an average trading volume of 2,290,000 shares, the days-to-cover ratio is currently 5.6 days.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $0.35 target price on shares of Asensus Surgical in a research report on Thursday, May 16th.
Read Our Latest Report on Asensus Surgical
Asensus Surgical Stock Performance
Asensus Surgical (NYSEAMERICAN:ASXC – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Asensus Surgical had a negative net margin of 902.25% and a negative return on equity of 184.10%. The firm had revenue of $1.12 million for the quarter, compared to analyst estimates of $1.10 million. On average, analysts anticipate that Asensus Surgical will post -0.24 EPS for the current year.
Institutional Trading of Asensus Surgical
A hedge fund recently raised its stake in Asensus Surgical stock. Virtu Financial LLC lifted its stake in shares of Asensus Surgical, Inc. (NYSEAMERICAN:ASXC – Free Report) by 834.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 249,019 shares of the company’s stock after purchasing an additional 222,368 shares during the quarter. Virtu Financial LLC owned about 0.09% of Asensus Surgical worth $57,000 as of its most recent filing with the Securities and Exchange Commission. 9.35% of the stock is currently owned by hedge funds and other institutional investors.
About Asensus Surgical
Asensus Surgical, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients.
Featured Stories
- Five stocks we like better than Asensus Surgical
- 3 Monster Growth Stocks to Buy Now
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- With Risk Tolerance, One Size Does Not Fit All
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- Profitably Trade Stocks at 52-Week Highs
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Asensus Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asensus Surgical and related companies with MarketBeat.com's FREE daily email newsletter.